{
    "clinical_study": {
        "@rank": "105912", 
        "arm_group": {
            "arm_group_label": "HSC835", 
            "arm_group_type": "Experimental", 
            "description": "Approximately 10 patients will undergo single umbilical cord blood transplantation using HSC835."
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and tolerability of using HSC835 in patients\n      undergoing single umbilical cord blood transplant."
        }, 
        "brief_title": "Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Single Umbilical Cord Blood Transplantation", 
            "Non-myeloablative Conditioning", 
            "Acute Myelocytic Leukemia", 
            "Acute Lymphocytic Leukemia", 
            "Chronic Myelogenous Leukemia", 
            "Myelodysplastic Syndrome", 
            "Chronic Lymphocytic Leukemia", 
            "Marginal Zone Lymphoma", 
            "Follicular Lymphomas", 
            "Large-cell Lymphoma", 
            "Hodgkin Lymphoma", 
            "Multiple Myeloma", 
            "Lymphoblastic Lymphoma", 
            "Burkitt's Lymphoma", 
            "Mantle-cell Lymphoma", 
            "Lymphoplasmacytic Lymphoma", 
            "Prolymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Prolymphocytic", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Waldenstrom Macroglobulinemia", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis that qualifies them for UCBT\n\n          -  Adequate organ function\n\n          -  Availability of eligible donor material\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breastfeeding women and women of child-bearing potential unless two\n             acceptable forms of contraception are being used\n\n          -  Human immunodeficiency virus (HIV) infection\n\n          -  Active infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930162", 
            "org_study_id": "CHSC835X2202"
        }, 
        "intervention": {
            "arm_group_label": "HSC835", 
            "description": "HSC835 is the expanded umbilical cord blood product used during single umbilical cord blood transplantation.", 
            "intervention_name": "HSC835", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "single umbilical cord blood transplantation, non-myeloablative conditioning", 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absence of graft failure in excess of treatment standard (DUCBT with NMA conditioning)", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930162"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of neutrophil recovery", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "measure": "Incidence of transplant-related mortality", 
                "safety_issue": "Yes", 
                "time_frame": "100 days, 1 year"
            }, 
            {
                "measure": "Overall survival and disease-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}